To date, an estimated 300 million people worldwide have been infected with chronic
hepatitis B virus (HBV). Although anti-HBV therapies have improved the long-term survival …

Objectives To develop EULAR recommendations for screening and prophylaxis of chronic
and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases …

The third decade of the 21 st century marks the beginning of a new era in the treatment of
rheumatoid arthritis (RA). Recently, after the introduction in clinical practice of different …

Abstract Background and Aim To investigate the risk of hepatitis B virus reactivation in
patients undergoing long-term tocilizumab therapy for rheumatoid arthritis. Method From …

Background The use of biologics poses a moderate to high risk for hepatitis B virus
reactivation (HBVr) in chronic carriers. Aim To determine the prevalence of HBVr with TNF …

Background Rheumatoid arthritis (RA) patients seropositive for hepatitis B core antibody
(HBcAb) and negative for hepatitis B surface antigen (HBsAg) are at risk of hepatitis B virus …

Objective Use of biologic and targeted synthetic DMARDs (b/tsDMARDs) in patients with pre‐
existing tuberculosis (TB), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection can …

Objective To evaluate the prevalence of infections, prevalence of hospitalisation due to
infections, the vaccination status and perceived screening of infections prior to the start of …

Rheumatoid arthritis (RA) is a multisystemic autoimmune disease that predominantly affects
synovial joints. It causes marked disability, reduces health-related quality of life, and leads to …

Background It is uncertain whether biological therapies would increase the risk of hepatitis
among patients with past hepatitis B virus (HBV) infection. This study aimed to evaluate the …